Until Eli Lilly abruptly pulled patients off of prasugrel, the blood thinning drug had been one of the more promising drugs for the large pharmaceutical company. A. Michael Lincoff, director of cardiovascular research at the Cleveland Clinic, was quoted in the Wall St. Journal as stating that in all likelihood the drug trial was suspended for safety reasons with bleeding the most likely safety factor. Lilly still plans to submit prasugrel to the FDA for approval by the end of this year.
For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.
Admitted to practice law in all federal multidistrict litigation courts, the California State Bar and the Florida Bar. His philosophy is to provide aggressive, quality representations and seek fair compensation for individuals and their families who have suffered injury, death, or sexual abuse.
Comments for this article are closed.